New York State Common Retirement Fund Has $444,000 Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

New York State Common Retirement Fund raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 3.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 16,435 shares of the company’s stock after purchasing an additional 471 shares during the quarter. New York State Common Retirement Fund’s holdings in Janux Therapeutics were worth $444,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of JANX. GAMMA Investing LLC lifted its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after purchasing an additional 1,574 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Janux Therapeutics during the 4th quarter worth $59,000. FNY Investment Advisers LLC raised its stake in shares of Janux Therapeutics by 6,928.6% during the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock worth $66,000 after purchasing an additional 2,425 shares during the period. Finally, KBC Group NV purchased a new stake in Janux Therapeutics in the 1st quarter worth about $66,000. 75.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the transaction, the insider directly owned 82,139 shares of the company’s stock, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.10% of the company’s stock.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $25.96 on Friday. The stock has a market cap of $1.54 billion, a PE ratio of -19.09 and a beta of 2.86. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock has a fifty day moving average of $24.80 and a 200 day moving average of $30.47.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.05. As a group, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James Financial started coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price for the company. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and a consensus price target of $91.89.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.